Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Same-day Discharge Following PCI: A Meta-analysis of RCTs
Author(s): Ngoc Huy Nguyen , Thanh Ngoc Le , Hoai Thi Thu Nguyen , et al Added: 7 months ago

Intervention
Comparative Analysis of Direct Oral Anticoagulants in Atrial Fibrillation
Author(s): Ton Duy Mai , Tri Huynh Quang Ho , Sy Van Hoang , et al Added: 8 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Targeted Lipid Control in Very-high-risk Indian Patients: Expert Insights
Author(s): Kausik Ray , Upendra Kaul , Srinivasa Rao , et al Added: 1 month ago

Guidelines & Statements
ESC 25: TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
Author(s): Philipp Lurz Added: 4 months ago
ESC Congress 2025 - New findings from a post-hoc analysis of TRISCEND II show that TTVR can reduce the rate of heart failure hospitalisations, particularly in the case of patients who present with massive or torrential TR - irrespective of baseline TR severity.Prof Philipp Lurz (University Mainz, DE) discusses new findings from the TRISCEND II trial, examining how baseline tricuspid regurgitation… View more

Intervention
ESC 25: The STEEER-AF Trial
Author(s): Dipak Kotecha Added: 4 months ago
ESC Congress 2025 - Exploratory findings from STEEER-AF suggest that a comprehensive educational programme for stroke prevention and rhythm control therapy improved outcomes for patients with atrial fibrillation.Dr Dipak Kotecha (University of Birmingham, Birmingham, UK) joins us to discuss findings from the STEEER-AF (NCT04396418) cluster randomised trial by the ESC and EHRA. The prospective,… View more

Electrophysiology & Arrhythmia
The XLIMIT Trial: XLIMUS® DES Shows Non-Inferiority to Synergy™ DES
Author(s): Luca Testa Added: 1 year ago
Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France.In this video interview, Dr Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.Specifically, the 6 to 9… View more

Intervention
EuroPCR 2025 Late-Breaking Trial Collection
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 8 months ago
Dive into our collection covering the hot line and late-breaking trials presented at EuroPCR 2025. Reviewing the sessions you don't want to miss, interventional experts Prof Nicolas Van MieghemandDr Joost Daemen will be leading our regular series View From the Thoraxcenter. For a deeper dive into the most anticipated trials, our Expert Interviews have you covered. View more

Intervention

MI/ACS
Immune Cell Traits and Heart Failure: A Mendelian Randomisation Study
Author(s): Wei Gao , Hui Wang , Jian-long Wang , et al Added: 2 months ago

Demographic

Heart Failure
Immune Cell Traits and Aortic Dissection: A Mendelian Randomisation Study
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 9 months ago

Electrophysiology & Arrhythmia

Inherited and Congenital Cardiac Conditions
AHA 25 Late-breaking Discussion: The BETTER-BP Trial
Author(s): John Dodson , Harriette Van Spall Added: 2 months ago
AHA Scientific Sessions 2025 — Late-breaker host Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by BETTER-BP Principal Investigator Dr John Dodson (NYU Langone Health, New York, US) to present the findings of this AHA late-breaking trial (NCT04114669).The BETTER-BP (Behavioral Economics Trial to Enhance Regulation of Blood Pressure) is a phase II pragmatic randomized… View more

Prevention & Chronic Conditions